Seattle Genetics has announced positive results in their Phase II trial of Brentuximab vedotin (SGN-35). This conjugated monoclonal antibody is currently being researched as a therapy for relapsed Hodgkin lymphoma that is not responsive to current treatment.
Conjugated monoclonal antibodies are designed to deliver toxins, radiation, or as in this case, cancer killing drugs directly to the lymphoma cells. The goal is to spare normal, healthy cells from the toxic effects of chemotherapy while targeting the cancer cells.
Brentuximab vedotin demonstrated a positive response in 75% of the subjects in the study. Seattle Genetics will release the full details of the study later on this month.